Vita 34 AG: First Dividend Payment

Leipzig, July 28, 2015

Today the shareholders at the Annual General Meeting of Vita 34 AG (WKN A0BL84) approved the proposal made by the Management and Supervisory Boards to pay a dividend in the amount of EUR 0.15 per share with a large majority thanks to the greatly improved income situation. This is equivalent to a dividend yield of some 2.5%.

In addition, within the course of changing the by-laws the number of Supervisory Board members was increased from three to six. Artur Isaev, Heinrich Sundermeyer and Ms. Gerrit Witschaß were elected as new Supervisory board members. Dr. med. Mariola Söhngen was elected as an alternate for the Supervisory Board. In the subsequent meeting of the Supervisory Board Dr. Hans-Georg Giering was confirmed as chairman and Alexander Starke elected as deputy chairman of the Supervisory Board, after Dr. Holger Födisch made this function available for personal reasons.

Prior to this, Dr. André Gerth, CEO of the largest stem cell bank in the German-speaking countries reported on the development of the company in fiscal year 2014, as well as in the first half-year 2015. He presented a very positive summary, not only for the individual reporting periods, but also in the overall context of the last three years. Providing insight into the strategic direction of Vita 34 AG, he directed attention to the future together with the shareholders in attendance.

“We have successfully developed our business in the last year. We had already set the course for this in 2012 and 2013. Over the last three years we have continuously increased total operating revenue, thereby keeping an increase in profitability in sight. After we were able to post the highest EBITDA in the company’s history in fiscal year 2013, we increased it again in fiscal year 2014. By creating the conditions for a dividend, we are now able to pay our shareholders a dividend for the first time. I am extremely pleased by this,” explained Dr. Gerth. He intends to ensure company success in the medium and long-term by consistently implementing the corporate strategy. Here, the three defined core growth elements will be central to future activities; a strengthening market leadership, product development, and the expansion of research and development.

The detailed voting results will be published soon in the Investor Relations section of the company website www.vita34group.de.

Company Profile

Vita 34 was founded in 1997 as the first private umbilical cord blood bank in Europe and, as a complete provider, offers collection logistics, preparation and storage of umbilical cord blood and cord tissue. The basis for its successful work is an outstanding position in the technological segment of cryo-preservation. Here, cells and tissue are preserved alive at some -190ºC for long periods of time, and can be used if needed in the context of medical treatment. Some 127,000 families have already made provisions for the future with a stem cell deposit at Vita 34.